Scarica l'app Stockscreener
9.31
0.43%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$9.37
Aprire:
$9.33
Volume 24 ore:
96,747
Relative Volume:
0.01
Capitalizzazione di mercato:
$10.93B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-2.9369
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+0.65%
1M Prestazione:
+4.25%
6M Prestazione:
-16.70%
1 anno Prestazione:
-20.26%
Intervallo 1D:
$9.30
$9.36
Intervallo di 1 settimana:
$8.835
$9.41
Portata 52W:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.31 | 10.84B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
153.32 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.73 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.92 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.51 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.50 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
What analysts say about Viatris Inc. stockExponential wealth increase - Autocar Professional
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com
What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - TradingView
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha
Viatris eye ointment fails late-stage study, shares fall - TradingView
Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com
Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com India
Viatris eye therapy fails to meet late-stage trial goal - TradingView
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN
Viatris (VTRS) Receives a Hold from Goldman Sachs - The Globe and Mail
Hypopituitarism Treatment Market Expansion Supported - openPR.com
Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest
Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest
Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):